INSIGHTS ON CELL & GENE COMMERCIALIZATION ISSUES

• Rethinking CGT Biotech Growth & Investment with Audrey Greenberg

  On the 100th episode of Cell & Gene: The Podcast, Host, Erin Harris, sits down with Audrey Greenberg, Founder and CEO of AG Capital Advisors. Audrey is the award-winning executive, board director, and strategic advisor with a proven track record of launching, scaling, and successfully exiting multi-billion-dollar ventures.

• 4 Key Solid Tumor Therapy Objectives iPSCs Can Help Achieve

  Induced pluripotent stem cells offer some key biologic, technical, and financial advantages over more established PBMC-derived therapies.

• Indian Biosimilar Companies Are Poised To Succeed In The Global Market

  For Indian biosimilar developers looking to capitalize on the upcoming patent cliff, it is vital to play to your strengths and identify strategies for breaking into competitive regulatory markets.

• How The Cell And Gene Therapy Market Is Taking Shape

  Targeting diseases at their genetic root, cell and gene therapies offer unprecedented hope. Yet, the industry grapples with balancing groundbreaking potential against the challenge of high-priced treatments.

• 2025 Cell Therapy Outlook From BPI West

  Bioprocess Online and Cell & Gene spoke with Takeda’s Amy Shaw at BPI West to discuss the industry and her key takeaways from the conference.

• A 5-Step Guide To Achieving Your Biosimilar Milestones On Time

  As the biologic patent cliff looms, biosimilar developers must strategically plot their approach to development and manufacturing to secure a corner of their market and reach their target patients.

• The Future Promise Of Advanced Therapies In Ophthalmology

  Six years after the first approved gene therapy in ophthalmology, the field is experiencing a surge of activity. Delve into the exciting potential of advanced therapies for eye diseases.

• Enabling Investment In Community Hospitals To Improve Patient Access

  Learn why enabling community hospitals to alleviate system constraints would usher a change in the future of cell and gene therapy delivery.

• Mobilizing Community Hospitals To Improve Patient Access To CGTs

  The patient, product, and value chains for cell and gene therapies are far different than traditional healthcare delivery and requires new and specialized sets of capabilities at hospitals.

• Collaboration Leads To CGT Progress At Astellas' West Coast Innovation Center

  Yoshi Shitaka, outgoing CSO and Richard Wilson, SVP, Primary Focus Lead (Genetic Regulation) at Astellas share how the company's West Coast Innovation Center serves as a central hub for AI, digital transformation, and more.